February 19, 2013

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

 

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Paris, France – February 19, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.